Nadja West, Director at Tempus AI, Inc. (TEM -0.51%), sold 3,000 shares of Class A Common Stock on Aug. 28, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $207,000 |
| Shares sold | 3,000 |
| Post-transaction shares (directly held) | 31,981 |
| Post-transaction value | $2.05 million |
Transaction value based on SEC Form 4 weighted average sale price ($69.00); post-transaction value based on Aug. 28, 2026, market close ($64.04).
Key questions
- What was the stated intent behind this transaction?
The sale was non-discretionary and executed pursuant to a Rule 10b5-1 trading plan established on May 15, 2026. These plans allow insiders to set up a pre-determined schedule for selling stock to avoid concerns regarding material non-public information. - How does this sale compare to the insider's remaining equity position?
The 3,000 shares sold represent 9.00% of Nadja West's direct equity stake before the transaction. Following the sale, the insider retains 31,981 shares of Class A Common Stock. - What has the equity's performance trend been leading up to this filing?
Shares of the healthcare technology company returned -13% over the one-period ending on the Aug. 28, 2026, the transaction date. The stock was priced at $63.05 as of the Aug. 31, 2026, market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-31) | $63.05 |
| Market Capitalization | $11.5 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue through diagnostic testing services and platform licensing to healthcare providers.
- The company's business model centers on providing end-to-end next-generation sequencing (NGS) testing solutions and clinical applications through its Tempus platform and Hub product, enabling healthcare providers to deliver precision diagnostics while capturing value from data analytics.
- The company serves physicians, healthcare providers, and clinical laboratories seeking advanced diagnostic capabilities, with primary customers including hospital systems, oncology centers, and diagnostic laboratories across the United States.
NASDAQ: TEM
Key Data Points
Tempus AI is a healthcare technology company with a $11.5 billion market capitalization, generating $1.4 billion in TTM revenue through its integrated diagnostic and analytics platform.
The company operates at scale with 3,800 employees. It maintains a competitive position through its bi-directional clinical integration capabilities and proprietary multimodal data repository. However, it remains in an investment phase with TTM net losses of $254 million as it scales its platform adoption and expands its diagnostic service offerings.
What this transaction means for investors
This sale shouldn't concern investors. It was executed under a Rule 10b5-1 plan, which insiders commonly use to execute planned transactions without appearing to act on material non-public information.
Moreover, it represented a small percentage of the director's stake. Following the sale, the director still retains over 90% of the previous stake in the company's stock.
Importantly, Tempus AI continues to see rapid growth. TTM revenue surged 50% year over year. It's still primarily focused on scaling revenue, as it hasn't reported a profit yet. TTM operating loss was $283 million.
The stock trades at 8 times trailing revenue. That valuation implies more robust top-line growth and the expectation that Tempus AI will significantly improve its profitability as the business scales.
